Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors

NCT06835387 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Small Bowel Adenocarcinoma

Interventions

DRUG: Nanoliposomal irinotecan
DRUG: Oxaliplatin
DRUG: 5 fluorouracil
DRUG: Leucovorin

Sponsor

Tiago Biachi de Castria

Collaborators

[object Object]
[object Object]